Nogueira José Barreto Cruz, Sena Laís Cristina Santana, Quintans Jullyana de Souza Siqueira, Almeida Jackson Roberto Guedes da Silva, França Alex Vianey Callado, Júnior Lucindo José Quintans
Department of Physiology, Federal University of Sergipe, São Cristóvão, SE, Brazil.
J Pharm Pract. 2012 Feb;25(1):85-8. doi: 10.1177/0897190011415687. Epub 2011 Sep 21.
This study sought to decribe, quantify, and classify any adverse reactions occurring in patients with chronic hepatitis C treated with peginterferon and ribavirin, as well as verify the occurrence of potential medication interactions. The most prevalent reactions were fatigue (84.8%), fever (83%), weight loss (80%), irritability (74%), and body pain (72%). Most of the reactions were classified as mild (95%), whereas 4.5% were classified as moderate and 0.4% as severe. Adverse reactions led to the rearrangement of therapy for 9 patients (20%), where there was a reduction in dose for 7 (15%), temporary interruption of treatment for 5 (11%), and permanent discontinuation for 3 patients (7%). A total of 11 potential medication interactions were identified in 9 patients (20%), with the most frequent between peginterferon-α2a and captopril (45%). Given the above, it is observed that the treatment of chronic hepatitis C is marked by several adverse reactions of varying severity, which can interfere with the patient's quality of life or in treatment compliance, and that can be aggravated by potential drug-drug interactions.
本研究旨在描述、量化和分类接受聚乙二醇干扰素和利巴韦林治疗的慢性丙型肝炎患者发生的任何不良反应，并验证潜在药物相互作用的发生情况。最常见的反应是疲劳（84.8%）、发热（83%）、体重减轻（80%）、易怒（74%）和身体疼痛（72%）。大多数反应被分类为轻度（95%），而4.5%被分类为中度，0.4%为重度。不良反应导致9例患者（20%）的治疗方案调整，其中7例（15%）剂量减少，5例（11%）暂时中断治疗，3例患者（7%）永久停药。9例患者（20%）共识别出11种潜在药物相互作用，最常见的是聚乙二醇干扰素-α2a与卡托普利之间的相互作用（45%）。鉴于上述情况，可以观察到慢性丙型肝炎的治疗以几种不同严重程度的不良反应为特征，这些不良反应可能会干扰患者的生活质量或治疗依从性，并且可能因潜在的药物-药物相互作用而加重。
